“Together we have been able to add and improve the processes to meet our customer needs, allowing us to offer high quality results and in a very short time to our patients.”

Alvaro Soto, General Manager, Roche Central America and the Caribbean

Cancer Genetics, Inc. (CGI) is transforming the diagnosis and clinical management of the most complex and difficult to treat cancers with a focus in hematologic, urogenital and gynecological malignancies. Founded in 1999, CGI is committed to offering high quality products and services that assist clinicians, oncologists and pathologists in devising treatment plans for their patients that will increase efficacy and reduce healthcare costs.

© 2013 Cancer Genetics, Inc. All rights reserved.

Main Phone: +1.201.528.9200Lab Phone: +1.201.528.9187Toll Free: 888.334.4988Fax Line: +1.201.528.9201

Client Services Hours:Monday-Friday: 8am-8pm ESTSaturday: 8am-4pm EST

Cancer Genetics, Inc.Meadows Office Complex201 Route 17 North, 2nd FloorRutherford, NJ 07070

Driving the Highest Levels of Patient Value World-Class Oncology-Focused

Diagnostics LaboratoryCAP Certification 7191582CLIA Accreditation 31D1038733Florida License 800018142Maryland License 1315New Jersey License 0002299New York License PFI 8192Pennsylvania License 031978

For more information, please visit www.cancergenetics.com

• Clinical management team with an average of 15 years diagnostic experience in oncology

• Expertise in next generation molecular diagnostics• Cutting-edge proprietary testing• Center of Excellence for CLL and DLBCL• Unique oncology focused R&D program• Clinical expertise with access to key opinion leaders• Research collaborations with major cancer centers (Memorial Sloan-Kettering Cancer Center, Cleveland Clinic)

• 99% of testing done under one roof allowing for superior turnaround time (TAT)

• Collaborations with pharmaceutical companies focused in clinical trials

• Easy access to test reports (HIPAA compliant): fax, email, web-based portal (cgireports.com) with EMR integration capacity

Cancer Genetics, Inc.

Recent Milestones

DLBCLCLL CLL/SLL MCL

2010 2011 2012

• Summation® Report is developed.

• MatBA®-CLL CLIA approved.

• Launch of CLL CompleteSM.• MatBA®-CLL New York State licensed.

• CGI establishes Select One™ Clinical Trials Services.

• Expansion of Dx lab services: JAK2 & MPL mutation analysis, EGFR mutation analysis.

• MatBA®-SLL CLIA & New York State approved.

• Expansion of Dx Lab services: Solid tumor, ALK Break Apart FISH, BRAF & KRAS mutation.

• Expansion of CLL CompleteSM testing; NOTCH1, TP53 mutation added.

• MatBA®-DLBCL CLIA & New York State approved.• UroGenRATM-Kidney CLIA and New York State

approved. • Launch of DLBCL CompleteSM.• Expansion of CLL CompleteSM testing; SF3B1

mutation added.• MatBA®-MCL CLIA approved.

2013

Cancer Genetics, Inc. | 201 Route 17 North, 2nd Floor, Rutherford, NJ 07070 | 1.201.528.9200 | www.cancergenetics.com

© 2013 Cancer Genetics, Inc. All rights reserved.

Clinical Management Team

Raju S.K. Chaganti, Ph.D.Founder and ChairmanDr. Raju S.K. Chaganti is the founder of CGI and has servied as chairman of the board of directors since the company’s inception. Dr. Chaganti is internationally recognized as a leader in cancer cytogenetics. Currently, Dr. Chaganti is the incumbent of the William Snee E. Chair at Memorial Sloan-Kettering Cancer Center (MSKCC) and is a faculty member of the Department of Medicine and Cell Biology Program. Dr. Chaganti received a Ph.D. in biology (genetics) from Harvard University Graduate School of Arts and Sciences and completed his post-doctoral training at the Medical Research Council of Great Britain. He completed a sabbatical in the Department of Tumor Biology at Karolinska Institute Stockholm, where he focused on experimental murine and tumorigenesis as well as immunology. Dr. Chaganti is certified by the American Board of Medical Genetics with a subspecialty in clinical cytogenetics.

Lan Wang, M.D.Medical DirectorDr. Wang joined CGI in 2008 as Medical Director. Dr. Wang is certified by the American Board of Pathology, as well as Hematopathology. In New Jersey, Dr. Wang holds a Medical License and Bioanalytical Laboratory Director License from the Board of Medical Examiners. She also has a Certificate of Qualification from New York State as a Laboratory Director in Histopathology and Cytopathology. Dr. Wang holds the position of Staff Pathologist/Hematopathologist and serves as a cancer liaison physician at Chilton Memorial Hospital in New Jersey.

Weiyi Chen, Ph.D., HCLD (ABB)Molecular Diagnostics DirectorDr. Weiyi Chen came to CGI in 2005. She has over 10 years of research experience in the genetics of lymphoma, and over 8 years of experience in clinical molecular diagnosis. She has published more than 10 peer-reviewed papers. Dr. Chen trained in the Molecular Research Laboratory at Memorial Sloan-Kettering Cancer Center. Dr. Chen is certified as a High-Complexity Clinical Laboratory Director (HCLD) from the American Board of Bioanalysis (ABB), and holds a certificate of qualification as a laboratory director from the New York State Department of Health. She is an active member of the Association of Molecular Pathology. Dr. Chen currently directs the Molecular Diagnostic Laboratory at CGI.

Kelly Corcoran, Ph.D.Clinical Laboratory Operations CoordinatorDr. Corcoran was awarded the New Jersey Commission on Science and Technology Fellowship. Her work is published in multiple peer-review journals. She has over 10 years of experience in flow cytometry. Among other responsibilities, Dr. Corcoran has developed and validated the Leukemia/Lymphoma antibody panel at CGI as well as developed several Standard Operating Procedures for sample handling, preparation and machine quality control.

Pal Singh-Kahlon, Ph.D., FACMGCytogenetics DirectorDr. Singh-Kahlon joined CGI in 2010 and has 20 years of experience in the field of clinical cytogenetics from academic institutions and reference laboratories. His work has been published in numerous peer-review journals and presented in multiple scientific conferences throughout the United States. Dr. Singh-Kahlon is recognized as a leader in the field of cytogenetics. He is board certified in clinical cytogenetics by the American Board of Medical Genetics. He holds a Certificate of Qualification (COQ) for the states of New York and New Jersey.

V. Subhadra Nandula, Ph.D., FACMG Associate Cytogenetics DirectorDr. Nandula’s focus has been on human genetics and especially cytogenetics for over 15 years. She spent 9 years at Columbia University and has published over 30 articles in international peer-reviewed journals. Experienced in solid tumor analysis, she has worked for over 7 years in Her-2/neu and oligodendroglioma FISH testing. In addition, she has 9+ years of experience in cytogenetics of hematological malignancies. She is certified by the American Board of Medical Genetics with a subspecialty in clinical cytogenetics. She also holds a Certificate of Qualification from the New York Department of Health in Cytogenetics.

Jane Houldsworth, Ph.D.Vice President of Research and DevelopmentDr. Houldsworth joined CGI in 2007. She has over 25 years of experience in translational research and has a long standing interest in the biology and genetics of lymphoma and male germ cell tumors. Dr. Houldsworth has published more than 60 peer-reviewed papers, 15 chapters, and continues to consult on academic research projects. She is an active member of the American Society of Hematology (ASH) and the American Association for Cancer Research (AACR). She also holds a New York State certificate of qualification as a laboratory director for oncology, molecular and cellular tumor markers.

032913